Polynucleotides Injectable Market Size, Share & Trends Analysis Report By Application (Eyes, Lips, Forehead, Jawline & Cheekbones), By End-use (MedSpas, Aesthetic & Cosmetic Centers), By Region, And Segment Forecasts, 2025 - 2030
Polynucleotides Injectable Market Size & Trends
The global polynucleotides injectable market size was estimated at USD 127.6 million in 2024 and is projected to grow at a CAGR of 15.1% from 2025 to 2030. Technological advancements in biotechnology primarily drive market growth, as do the increasing demand for skin rejuvenation, personalized medicine, and investments in research and development (R&D). According to an article published by PMTA Journal in March 2024, polynucleotide injections gained prominence in aesthetic medicine due to their beneficial effects on skin, hair, and other tissues, as explored in this comprehensive review.
The growing demand for advanced skin rejuvenation treatments is a primary driver of the polynucleotides injectable industry. As individuals seek more effective solutions to address signs of aging, such as fine lines, wrinkles, and skin laxity, the interest in novel injectable treatments such as polynucleotides has surged. For instance, a recent study published in the journal Dermatologic Therapy found that polynucleotide injections improved skin tone, fine lines, skin elasticity, and hydration in patients in their 30s and 40s.
The increasing focus on personalized medicine also contributed to the growth of the market. As healthcare providers and patients alike seek customized approaches to skin rejuvenation, polynucleotides' ability to stimulate the body's natural collagen production and cellular regeneration has made them a popular choice. This trend is particularly evident in the rising demand for personalized aesthetic treatments, which is expected to continue expanding the market.
Finally, integrating innovative technologies, such as digital imaging and automated injection systems, has further propelled the polynucleotides injectable industry. These advancements improved polynucleotide injections' precision, consistency, and safety, making them more appealing to healthcare providers and patients. As the aesthetic industry continues to evolve, incorporating cutting-edge technologies is expected to remain a vital driver of the polynucleotide injectable industry. For instance, in 2022, Pulse Light Clinic in London is introducing PhilArt by Croma, an innovative polynucleotide injection treatment recognized for significantly enhancing skin hydration, boosting elasticity, and stimulating natural collagen production - a pioneering advancement in skin rejuvenation.
Global Polynucleotides Injectable Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global polynucleotides injectable market report based on application, end-use, and region:
- Application Outlook (Revenue, USD Million, 2018 - 2030)
- Eyes
- Lips
- Forehead
- Jawline & Cheekbones
- Others
- End-use Outlook (Revenue, USD Million, 2018 - 2030)
- MedSpas
- Aesthetic & Cosmetic Centers
- Hospitals
- Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East and Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Application
- 1.2.2. End Use
- 1.2.3. Regional scope
- 1.2.4. Estimates and forecasts timeline.
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR’s internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Application outlook
- 2.2.2. End Use outlook
- 2.2.3. Regional outlook
- 2.3. Competitive Insights
- Chapter 3. Polynucleotides Injectable Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook.
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Technological advancements
- 3.2.1.2. Growing demand for skin rejuvenation
- 3.2.1.3. Shifting focus towards regenerative aesthetics
- 3.2.2. Market restraint analysis
- 3.2.2.1. Limited access to the treatments
- 3.3. Polynucleotides Injectable Market Analysis Tools
- 3.3.1. Industry Analysis - Porter’s
- 3.3.2. PESTEL Analysis
- Chapter 4. Polynucleotides Injectable Market: Application Estimates & Trend Analysis
- 4.1. Application Market Share, 2024 & 2030
- 4.2. Segment Dashboard
- 4.3. Global Polynucleotides Injectable Market by Application Outlook
- 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 4.4.1. Eyes
- 4.4.1.1. Eyes market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.2. Lips
- 4.4.2.1. Lips market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.3. Forehead
- 4.4.3.1. Forehead market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.4. Jawline & Cheekbones
- 4.4.4.1. Jawline & Cheekbones market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.5. Others
- 4.4.5.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
- Chapter 5. Polynucleotides Injectable Market: End Use Estimates & Trend Analysis
- 5.1. End Use Market Share, 2024 & 2030
- 5.2. Segment Dashboard
- 5.3. Global Polynucleotides Injectable Market by End Use Outlook
- 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 5.4.1. MedSpas
- 5.4.1.1. MedSpas market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.2. Aesthetic & Cosmetic Centers
- 5.4.2.1. Aesthetic & cosmetic centers market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.3. Hospitals
- 5.4.3.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
- Chapter 6. Polynucleotides Injectable Market: Regional Estimates & Trend Analysis
- 6.1. Regional Market Share Analysis, 2024 & 2030
- 6.2. Regional Market Dashboard
- 6.3. Global Regional Market Snapshot
- 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 6.5. North America
- 6.5.1. North America
- 6.5.2. U.S.
- 6.5.2.1. Key country dynamics
- 6.5.2.2. Regulatory framework
- 6.5.2.3. Competitive scenario
- 6.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.3. Canada
- 6.5.3.1. Key country dynamics
- 6.5.3.2. Regulatory framework
- 6.5.3.3. Competitive scenario
- 6.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.4. Mexico
- 6.5.4.1. Key country dynamics
- 6.5.4.2. Regulatory framework
- 6.5.4.3. Competitive scenario
- 6.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6. Europe
- 6.6.1. Europe
- 6.6.2. UK
- 6.6.2.1. Key country dynamics
- 6.6.2.2. Regulatory framework
- 6.6.2.3. Competitive scenario
- 6.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6.3. Germany
- 6.6.3.1. Key country dynamics
- 6.6.3.2. Regulatory framework
- 6.6.3.3. Competitive scenario
- 6.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6.4. France
- 6.6.4.1. Key country dynamics
- 6.6.4.2. Regulatory framework
- 6.6.4.3. Competitive scenario
- 6.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6.5. Italy
- 6.6.5.1. Key country dynamics
- 6.6.5.2. Regulatory framework
- 6.6.5.3. Competitive scenario
- 6.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6.6. Spain
- 6.6.6.1. Key country dynamics
- 6.6.6.2. Regulatory framework
- 6.6.6.3. Competitive scenario
- 6.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6.7. Denmark
- 6.6.7.1. Key country dynamics
- 6.6.7.2. Regulatory framework
- 6.6.7.3. Competitive scenario
- 6.6.7.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6.8. Sweden
- 6.6.8.1. Key country dynamics
- 6.6.8.2. Regulatory framework
- 6.6.8.3. Competitive scenario
- 6.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6.9. Norway
- 6.6.9.1. Key country dynamics
- 6.6.9.2. Regulatory framework
- 6.6.9.3. Competitive scenario
- 6.6.9.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
- 6.7. Asia Pacific
- 6.7.1. Asia Pacific
- 6.7.2. Japan
- 6.7.2.1. Key country dynamics
- 6.7.2.2. Regulatory framework
- 6.7.2.3. Competitive scenario
- 6.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
- 6.7.3. China
- 6.7.3.1. Key country dynamics
- 6.7.3.2. Regulatory framework
- 6.7.3.3. Competitive scenario
- 6.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
- 6.7.4. India
- 6.7.4.1. Key country dynamics
- 6.7.4.2. Regulatory framework
- 6.7.4.3. Competitive scenario
- 6.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
- 6.7.5. Australia
- 6.7.5.1. Key country dynamics
- 6.7.5.2. Regulatory framework
- 6.7.5.3. Competitive scenario
- 6.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
- 6.7.6. South Korea
- 6.7.6.1. Key country dynamics
- 6.7.6.2. Regulatory framework
- 6.7.6.3. Competitive scenario
- 6.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
- 6.7.7. Thailand
- 6.7.7.1. Key country dynamics
- 6.7.7.2. Regulatory framework
- 6.7.7.3. Competitive scenario
- 6.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
- 6.8. Latin America
- 6.8.1. Latin America
- 6.8.2. Brazil
- 6.8.2.1. Key country dynamics
- 6.8.2.2. Regulatory framework
- 6.8.2.3. Competitive scenario
- 6.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
- 6.8.3. Argentina
- 6.8.3.1. Key country dynamics
- 6.8.3.2. Regulatory framework
- 6.8.3.3. Competitive scenario
- 6.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
- 6.9. MEA
- 6.9.1. MEA
- 6.9.2. South Africa
- 6.9.2.1. Key country dynamics
- 6.9.2.2. Regulatory framework
- 6.9.2.3. Competitive scenario
- 6.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
- 6.9.3. Saudi Arabia
- 6.9.3.1. Key country dynamics
- 6.9.3.2. Regulatory framework
- 6.9.3.3. Competitive scenario
- 6.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
- 6.9.4. UAE
- 6.9.4.1. Key country dynamics
- 6.9.4.2. Regulatory framework
- 6.9.4.3. Competitive scenario
- 6.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
- 6.9.5. Kuwait
- 6.9.5.1. Key country dynamics
- 6.9.5.2. Regulatory framework
- 6.9.5.3. Competitive scenario
- 6.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
- Chapter 7. Competitive Landscape
- 7.1. Recent Developments & Impact Analysis, By Key Market Participants
- 7.2. Company/Competition Categorization
- 7.3. Vendor Landscape
- 7.3.1. List of key distributors and channel partners
- 7.3.2. Key customers
- 7.3.3. Key company market share analysis, 2024
- 7.3.4. PHARMA RESEARCH
- 7.3.4.1. Company overview
- 7.3.4.2. Financial performance
- 7.3.4.3. Others benchmarking
- 7.3.4.4. Strategic initiatives
- 7.3.5. BIOPLUS CO., LTD.
- 7.3.5.1. Company overview
- 7.3.5.2. Financial performance
- 7.3.5.3. Others benchmarking
- 7.3.5.4. Strategic initiatives
- 7.3.6. LG Chem
- 7.3.6.1. Company overview
- 7.3.6.2. Financial performance
- 7.3.6.3. Others benchmarking
- 7.3.6.4. Strategic initiatives
- 7.3.7. AMEELA
- 7.3.7.1. Company overview
- 7.3.7.2. Financial performance
- 7.3.7.3. Others benchmarking
- 7.3.7.4. Strategic Initiatives
- 7.3.8. Mastelli
- 7.3.8.1. Company overview
- 7.3.8.2. Financial performance
- 7.3.8.3. Others benchmarking
- 7.3.8.4. Strategic initiatives
- 7.3.9. Pluryal, Promoitalia Laboratories, Fox Pharma, BR Pharm, DermaFocus
- 7.3.9.1. Company overview
- 7.3.9.2. Financial performance
- 7.3.9.3. Others benchmarking
- 7.3.9.4. Strategic initiatives
- 7.3.10. Promoitalia Laboratories
- 7.3.10.1. Company overview
- 7.3.10.2. Financial performance
- 7.3.10.3. Others benchmarking
- 7.3.10.4. Strategic initiatives
- 7.3.11. Fox Pharma
- 7.3.11.1. Company overview
- 7.3.11.2. Financial performance
- 7.3.11.3. Others benchmarking
- 7.3.11.4. Strategic initiatives
- 7.3.12. BR Pharm
- 7.3.12.1. Company overview
- 7.3.12.2. Financial performance
- 7.3.12.3. Others benchmarking
- 7.3.12.4. Strategic initiatives
- 7.3.13. DermFocus
- 7.3.13.1. Company overview
- 7.3.13.2. Financial performance
- 7.3.13.3. Others benchmarking
- 7.3.13.4. Strategic initiatives
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook